S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
66,000% upside on tiny biotech? (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Major Financial Crisis Could Hit America (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Major Financial Crisis Could Hit America (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
66,000% upside on tiny biotech? (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Major Financial Crisis Could Hit America (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Major Financial Crisis Could Hit America (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
66,000% upside on tiny biotech? (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Major Financial Crisis Could Hit America (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Major Financial Crisis Could Hit America (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
66,000% upside on tiny biotech? (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Major Financial Crisis Could Hit America (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Major Financial Crisis Could Hit America (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
NASDAQ:RIGL

Rigel Pharmaceuticals (RIGL) Stock Forecast, Price & News

$1.56
+0.05 (+3.31%)
(As of 06/7/2023 ET)
Compare
Today's Range
$1.47
$1.60
50-Day Range
$1.12
$1.82
52-Week Range
$0.64
$2.04
Volume
2.71 million shs
Average Volume
2.88 million shs
Market Capitalization
$270.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.21

Rigel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
169.8% Upside
$4.21 Price Target
Short Interest
Healthy
4.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Rigel Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.30) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

404th out of 981 stocks

Pharmaceutical Preparations Industry

180th out of 462 stocks


RIGL stock logo

About Rigel Pharmaceuticals (NASDAQ:RIGL) Stock

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Receive RIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RIGL Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Q1 2023 Rigel Pharmaceuticals Inc Earnings Call
Rigel Pharmaceuticals Inc. Q1 Loss decreases, beats estimates
12 Best Low-Priced Growth Stocks To Buy
See More Headlines

RIGL Price History

RIGL Company Calendar

Last Earnings
3/07/2023
Today
6/07/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RIGL
CUSIP
76655960
Employees
165
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$4.21
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+169.8%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$-58,570,000.00
Pretax Margin
-34.47%

Debt

Sales & Book Value

Annual Sales
$120.24 million
Book Value
($0.08) per share

Miscellaneous

Free Float
162,500,000
Market Cap
$270.93 million
Optionable
Optionable
Beta
0.72

Social Links


Key Executives

  • Raul R. Rodriguez
    President, Chief Executive Officer & Director
  • Dean L. Schorno
    Chief Financial Officer & Executive Vice President
  • Esteban S. Masuda
    Executive Vice President-Research
  • David A. Santos
    Chief Commercial Officer & Executive VP
  • Raymond J. Furey
    Secretary, Executive VP & General Counsel













RIGL Stock - Frequently Asked Questions

Should I buy or sell Rigel Pharmaceuticals stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RIGL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RIGL, but not buy additional shares or sell existing shares.
View RIGL analyst ratings
or view top-rated stocks.

What is Rigel Pharmaceuticals' stock price forecast for 2023?

7 Wall Street research analysts have issued 12 month target prices for Rigel Pharmaceuticals' shares. Their RIGL share price forecasts range from $1.00 to $15.00. On average, they predict the company's share price to reach $4.21 in the next year. This suggests a possible upside of 169.8% from the stock's current price.
View analysts price targets for RIGL
or view top-rated stocks among Wall Street analysts.

How have RIGL shares performed in 2023?

Rigel Pharmaceuticals' stock was trading at $1.50 on January 1st, 2023. Since then, RIGL stock has increased by 4.0% and is now trading at $1.56.
View the best growth stocks for 2023 here
.

When is Rigel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our RIGL earnings forecast
.

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its quarterly earnings results on Tuesday, March, 7th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.08. The biotechnology company had revenue of $51.28 million for the quarter, compared to analysts' expectations of $37.55 million. Rigel Pharmaceuticals had a negative net margin of 34.47% and a negative trailing twelve-month return on equity of 2,419.00%. During the same quarter in the previous year, the company earned ($0.13) EPS.

What ETFs hold Rigel Pharmaceuticals' stock?

ETFs with the largest weight of Rigel Pharmaceuticals (NASDAQ:RIGL) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC),

What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO?

6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.80%), BlackRock Inc. (8.13%), Acadian Asset Management LLC (2.14%), State Street Corp (1.98%), Geode Capital Management LLC (1.89%) and FMR LLC (1.63%). Insiders that own company stock include David A Santos, Dean L Schorno and Raul R Rodriguez.
View institutional ownership trends
.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $1.56.

How much money does Rigel Pharmaceuticals make?

Rigel Pharmaceuticals (NASDAQ:RIGL) has a market capitalization of $270.93 million and generates $120.24 million in revenue each year. The biotechnology company earns $-58,570,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

How many employees does Rigel Pharmaceuticals have?

The company employs 165 workers across the globe.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.rigel.com. The biotechnology company can be reached via phone at (650) 624-1100, via email at ir@rigel.com, or via fax at 650-624-1101.

This page (NASDAQ:RIGL) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -